Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tpdelansbsalbac
- Development stage
- Phase 2
- Lead developer
- The First Affiliated Hospital of Xinxiang Medical College
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intraperitoneal, Intrapleural, Intravitreal
01
Overview
tpdelansbsalbac is a recombinant, live-attenuated, and hypoxia-targeted strain of *Salmonella typhimurium* (YB1) developed by Beijing Transebacillus Biotech for the treatment of solid tumors and malignant effusions. The bacterium is engineered to selectively replicate in the hypoxic microenvironment of tumors by placing the essential *asd* (aspartate-semialdehyde dehydrogenase) gene under the control of a hypoxia-inducible promoter. This modification, along with the deletion of the *rpoS* gene, ensures that the bacteria remain localized to the tumor site, minimizing systemic toxicity while inducing oncolytic effects and stimulating a local immune response. It is currently being evaluated in Phase I/II clinical trials for patients with malignant pleural and abdominal effusions.
- Other names
- tpdelansbsalbacTransebacillusSalmonella typhimurium YB1
Beyond the preview
Go deeper on tpdelansbsalbac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tpdelansbsalbac.